Emergency lights have been turned on in the derivatives market as well due to the sharp surge in the spot price of Samcheondang Pharmaceutical. The Korea Exchange announced on the 17th that it would expand the price limit for Samcheondang Pharmaceutical stock futures to Level 2 (20%), wider than the existing limit, at 12:43 PM.

According to the exchange, as of 12:43 PM on this day, the reference item price of Samcheondang Pharmaceutical stock futures rose 10% compared to the base price, meeting the requirements for expanding the price limit. The expanded price limit was actually applied from 12:48 PM and 7 seconds, five minutes after the announcement. If the reference item price rises an additional 20% or more compared to the base price in the future, the stock futures price limit will be further expanded to Level 3, or 30%, after five minutes.

This measure is an upward price limit expansion in accordance with Article 56-2 of the Enforcement Detailed Rules of the Derivatives Market Business Regulations. The exchange urged investors to exercise special caution, noting that after the price limit expansion, the real-time price limit device is not applied, and prices may fluctuate sharply due to previously submitted market orders and the like.

The market analyzes that Samcheondang Pharmaceutical is exhibiting high volatility in both the spot and futures markets as strong buying pressure has flowed in, driven by recent expectations for new drug development and prospects for overseas business expansion.

A securities industry official said, "The expansion of the stock futures price limit means that the volatility of the underlying asset has become very significant," adding, "In a phase of short-term surge, investment risk management in response to increased volatility is necessary."

[※ This article was written with AI assistance and is not intended to solicit investment. Investment decisions and responsibilities lie with the investor.]